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The Effectiveness of Heart Failure Disease Management:
Initial Findings from a Comprehensive Program
JANICE L. CLARKE, R.N., B.B.A., and DAVID B. NASH, M.D., M.B.A.
ABSTRACT
A prevalent, chronic condition among members of the mushrooming elderly population in
the United States, heart failure (HF) is a logical focus for population-based disease manage-
ment. Evidence supporting the premise that multidisciplinary interventions can significantly
improve clinical outcomes while decreasing the cost of medical care for people with HF is
steadily mounting. A growing number of controlled and observational studies focus on the
effects of HF disease management on re-admission rates, length of stay, and improvement in
appropriate diagnostic testing and prescribing. This paper describes a large-scale, compre-
hensive HF program and reports on clinical quality, utilization, and financial outcomes ob-
served after 1 year. The preliminary findings strengthen the case for comprehensive HF dis-
ease management as an effective means for improving clinical outcomes and reducing total
medical costs for large patient populations.
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INTRODUCTION
ADEVASTATING DISEASE in terms of its preva-lence, morbidity and mortality, and finan-
cial costs, heart failure (HF) ranks high on the
list of chronic conditions burdening the U.S.
health care system today. Recent statistics show
that HF affects an estimated 5 million Ameri-
cans, with approximately 400,000 new cases di-
agnosed each year.1 Jolting as these statistics
are, they are likely an underestimation of the
actual incidence of HF. In one retrospective re-
view of 225 randomly selected patients, inves-
tigators concluded that many patients admit-
ted with shortness of breath and low left
ventricular ejection fraction had HF but are not
diagnosed.2
A patient’s prospects for survival following
a diagnosis of HF are bleaker than those for
most forms of cancer. HF carries an overall
mortality rate of 50% within 5 years of diag-
nosis. Croft et al.3 reported a 6-year mortality
rate secondary to HF of 84% in men and 77%
in women. Despite continued advances in med-
ical treatment for the disease, the mortality and
morbidity attributed to HF have continued to
rise. Between 1979 and 1997, HF deaths in-
creased by 145% and HF hospitalizations rose
by 155.2%.4
When viewed in the context of an aging U.S.
population, the implications of the preceding
take on added dimension. As 75 million “baby-
boomers” age, the number of Americans over
the age of 65 is expected to double over the next
30 years.5 The incidence of HF increases with
age: In people over the age of 65 it approaches
1%, and in the 70–79 age group it increases to
4%. By the year 2007, the prevalence of HF is
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expected to reach 10 million cases in the United
States alone.6
According to Medicare program (HCFA/
CMS) data, expenditures for HF in 1991 were
higher than the combined expenditures for the
five most common diagnosis-related groups for
cancer, and higher than those for myocardial
infarction.7 In dollars, HF management, in-
cluding hospitalization costs (inpatient and
pharmacy) and outpatient visits, approached
$38 billion. By 1996, HF accounted for 2.8% of
all hospital discharges and 22% of all dis-
charges for cardiovascular disease in the
United States. “Based on an increase in the
number of patients with heart failure since
1991, the total cost for HF management for 1999
is estimated to approach $56 billion.”6 Data
suggest that half of the 15–30% HF related re-
admissions (within 90 days) are preventable.
Barriers to effective outpatient management
Medical management after the onset of HF is
challenging for both physicians and patients.
For the primary care physician (PCP), each new
clinical trial and each new or revised guideline
increases the complexity of the care and treat-
ment of the patient with HF, particularly the
patient with a co-existing chronic condition. A
majority of patients with HF have one or more
comorbid conditions. Diabetes, a complex dis-
ease in its own right, is a common co-existing
condition, as are hypertension, hypercholes-
terolemia, and depression.
National guidelines for the medical manage-
ment of patients with HF, published by the
Agency for Healthcare Research and Quality
(AHRQ) and the American College of Cardiol-
ogy (ACC)/American Heart Association (AHA),
are readily available from a variety of sources,
including medical professional organizations,
government agencies, managed care organiza-
tions, and other health care insurers. However,
the administrative data [for example, Health
Plan Employer Data and Information Set
(HEDIS®; National Committee for Quality As-
surance) data] reported by health plans show
persistent and disturbing variances between
recommended treatment and standard prac-
tice. Physician adherence to the established
guidelines for the use of angiotensin convert-
ing enzyme (ACE) inhibitors has been the 
focus of numerous studies. While there is plen-
tiful evidence that ACE inhibitors reduce dis-
ability, improve functional capacity, and pro-
long life in patients with HF, studies show that
physicians continue to underutilize these
drugs. In one study, only 73% of the patients
most likely to benefit from and tolerate such
therapy were prescribed ACE inhibitors at dis-
charge from the hospital.8
Barriers to effective treatment of HF are not
limited to physician issues. Cardiovascular dis-
ease often arises from unhealthy lifestyle pat-
terns such as smoking, poor diet, or inactivity.
Patients with HF often find it difficult to make
necessary changes in behavior and lifestyle.
Chin and Goldman9 found that some admis-
sions for HF could be attributed to patient in-
ability to adhere to dietary (salt) restrictions or
medication regimens. Psychosocial factors such
as depression, hostility, and the social isolation
often associated with age and infirmity have all
been shown to contribute independently to
mortality and morbidity in patients with car-
diovascular disease—and anger and hostility
are strongly associated with the development
of HF.
Of particular interest are findings suggesting
that as many as 15% of hospital readmissions for
HF are related to underutilization of prescribed
medication.10 In his discussion of the economic
burden of HF, O’Connell6 estimates that “if phar-
macologic and behavioral approaches were com-
bined, the five-year mortality rate could be re-
duced by as much as 50 percent.”
Disease management approaches to HF
Successful outpatient management models
have been described in the literature, each em-
ploying a systematic approach to HF care and
each resulting in improved quality as mea-
sured by decreased utilization of health care 
resources or by increased utilization of appro-
priate medications. Multiple approaches in-
cluding outpatient HF clinics, predischarge
team planning, off-site case management with
home visits, and Internet-based interventions
have been developed and researched. Positive
findings consistently include reduction in ad-
verse clinical outcomes (e.g., readmissions) and
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costs with corresponding improvement in
medication use and quality-of-life (QOL) indi-
cators.11–15 In a critical review of the evidence
for HF disease management programs prior to
1999, Rich16 catalogued 10 observational stud-
ies that suggested an association between mul-
tidisciplinary approaches and reduced inpa-
tient admissions and length of stay (LOS),
improved QOL, and lower overall cost of care.
He also reviewed six randomized studies that
effectively reduced inpatient utilization, im-
proved functional capacity, and enhanced pa-
tient knowledge and compliance with treat-
ment regimens. The long-term impact and
cost-effectiveness of these models have yet to
be determined.
Evidence of value of programs focused on
developing self-management skills continues
to mount. A recent AHRQ study of self-man-
agement programs at several university-based
centers concluded that such programs improve
health and reduce use of health care resources
by people with chronic diseases.17 In evaluat-
ing HF disease management programs, brief in-
terventions (requiring 80–120 min of physician
and other health care provider time) have been
shown to be effective for patients who are
highly motivated, have less comorbidity, are
better educated, and have more social support.
For patients who need more motivation, sup-
port, or skills training than a brief intervention
can provide, intensive interventions have been
shown to produce a greater effect than brief in-
terventions.18
PROGRAM DESCRIPTION
American Healthways Corporation (AMHC)
provides the Cardiac HealthwaysSM HF Pro-
gram described herein to members of a large
(over 800,000 members) midwestern U.S. com-
mercial health plan. Holistic in approach, the
program is designed to coordinate all health
care needs of participants, not just those related
to the managed disease. Stated program goals
include promoting the physician–patient rela-
tionship; supporting the physician with patient
management through regular health assess-
ments, symptom monitoring, and ongoing pa-
tient education; improving the health status of
the population; and, as a result, reducing the
cost of medical care. The program is grounded
in nationally recognized, evidence-based guide-
lines for medical management and treat-
ment of heart failure, including the ACC/
AHA Guidelines for the Evaluation and Man-
agement of Heart Failure; the National Cho-
lesterol Education Program Guidelines (ATP
III); the Joint National Committee for Treat-
ment of High Blood Pressure (JNC VI); and the
ACC/AHA Guidelines for Preventing Heart
Attack and Death in Patients with Atheroscle-
rotic Cardiovascular Disease: 2001 Update.
Education and support for PCPs
Cooperation and communication with the
PCP are essential to the success of a disease
management program developed around a pri-
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TABLE 1. FOCUSED INTERVENTIONS FOR PCPS
Physician intervention Frequency
Introductory letter Initially
Cardiac care guidelines Annually, as updated
Sample participant “welcome kit” Initially
Provider service manager visit Minimum once
Single topic sheet: beta-blocker indications and dosing
Single topic sheet: ACE inhibitor indications and dosing
Participant medication list Semiannually
Computer-generated alerts/reminders Semiannually
Patients not on ACE inhibitors or beta-blockers
Home-monitoring alerts re weight, blood pressure, pulse Daily, as needed
Cardiac-specific newsletter Quarterly
Toll-free hotline Ongoing
Flow sheet for documenting compliance with guidelines Initial and annually
Satisfaction survey Minimum annually
mary care “gatekeeper.” The PCP is brought
into the loop at the time of a patient’s enroll-
ment, and frequent contact is made throughout
the patient’s participation in the program
(Table 1). Program staff sends an introductory
letter along with a synopsis of the most recent
ACC/AHA cardiac care guidelines to the PCP.
Medication list updates, including both phar-
maceutical claims data and patient self-re-
ported information, are sent periodically to the
PCP for all her/his participating patients. Soft-
ware-generated reports are sent to alert physi-
cians of HF patients who may be appropriate
for certain treatments, such as ACE inhibitors
or beta-blockers, and whose pharmacy records
indicate that these medications are not pre-
scribed.
A group of specially trained registered
nurses, assigned to physician territories, visit
offices to orient PCPs and their office staffs to
the HF program. They provide education, of-
fer encouragement and tools to assist the PCP
in adhering to standards of care (e.g., indica-
tions for prescribing ACE inhibitors), and es-
tablish collaborative relationships to facilitate
follow-up visits.
Focused interventions for program participants
Program participant interventions and asso-
ciated frequencies are listed in Table 2. The key
participant intervention is the “Care Call.”
Care Calls, regularly scheduled telephone con-
tacts initiated by the program’s nursing staff,
serve as a basis for conducting health assess-
ments as well as providing disease-specific 
education, advocacy, and provider treatment
plan support on an ongoing basis. Participant
responses to the assessments direct the nurses
to educational points for discussion with the
participant. At each follow-up phone call,
nurses use a “follow-up assessment” script de-
signed to quickly identify any decompensating
symptoms. In the event of urgent symptoms,
the nurses reinforce self-management by as-
suring that patients make contact with their
PCPs. All HF participants meet criteria for the
highest level (Level 4) in the program’s pro-
prietary population stratification model, and,
accordingly, they are referred to nurses with
the highest level of training for Care Calls. On
the initial call, the nurse conducts a thorough
HF assessment to further stratify the patient,
which, in turn, drives the scheduled Care Call
frequency. Care Calls range from weekly to
every 6 weeks for HF members.
The nurse conducts a thorough medication
review on the initial call, cataloguing all med-
ications the participant is taking along with
dosages and frequencies, compliance, medica-
tion knowledge, and attitude toward taking
medications. From this discussion, the nurse is
directed to education points on medications
and suggested questions for the participant to
ask his/her physician (i.e., “Would a beta-
blocker be a good medication for me to be on?”
“Should I be taking an ACE inhibitor?”). Dur-
ing follow-up calls, the nurse asks about any
changes in medications.
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TABLE 2. FOCUSED INTERVENTIONS FOR HF PROGRAM PARTICIPANTS
Participant interventions Frequency
Letter of introduction and welcome kit On identification
Standards of care mailings Quarterly
Health education mailings As requested by member or PCP
Cardiac-specific newsletters Quarterly
Care Calls
Initial welcome call Once
Assessments (e.g., HF, medication, health status, Annually
depression risk screen, QOL)
Scheduled follow-up calls and re-assessment According to protocol
In-home telemonitoring (weight, blood pressure, pulse) According to protocol
Self-Care Goal Agreement Ongoing
CHF toll-free hotline Ongoing
CHF website Ongoing
Satisfaction survey Minimum annually
Whenever the nurse perceives a participant
knowledge deficit, he/she supplements the dis-
cussion with a mailed single topic information
sheet. Examples include information specific to
medications such as ACE inhibitors, beta-block-
ers, aspirin, or statins; nutrition (low sodium
diet); or congestive HF (CHF) (e.g., “What is
CHF?”). All information from calls is entered in
the HF participant’s electronic medical record.
Another important element in the Care Call
is the Self-Care Goal Agreement. A product of
the nurse–participant telephone discussions,
the agreement documents the participant’s
identified self-care goals. The goals are directed
toward behavior modification that supports
both the physician’s treatment plan and the
participant’s objectives.
By means of these regular interactions with
program participants, nurses are able to iden-
tify those patients most likely to benefit from
in-home monitoring. After consultation with a
patient’s PCP, the nurse may arrange for elec-
tronic monitoring of the patient’s weight, heart
rate, and blood pressure. Patient selection and
the duration of the in-home monitoring are de-
termined by protocol.
SUBJECTS AND METHODS
The program is provided on an engagement
basis to health plan members (i.e., all Com-
mercial and Medicare 1 Choice members iden-
tified as having HF are automatically included
in the program unless they exercise their right
to “opt-out” by choosing not to participate).
Identification is made on the basis of a mini-
mum of one HF inpatient claim/encounter or
two HF outpatient claims/encounters within a
12-month period with matching primary or
secondary ICD-9 diagnosis codes listed in
Table 3. Types of claims include professional,
facility, and ancillary (inpatient, outpatient, home
health, pharmacy, durable medical equipment,
and any other ancillary) charges. Once identi-
fied, members and their PCPs are welcomed to
the program via introductory letters, welcome
kits, and Standards of Care notices. An elec-
tronic database equipped with proprietary soft-
ware enables program staff to track participants’
medical claims, drug prescriptions, nature and
frequency of laboratory tests, and, in most cases,
laboratory test results.
INITIAL RESULTS
Table 4 provides summary demographic
data for program participants. Participant char-
acteristics were well balanced with respect to
age and gender for the baseline and report pe-
riods. Change in male–female ratio over the re-
port period was marginally significant (p ,
0.05). More than one-third of participants had
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TABLE 3. IDENTIFICATION SCHEME FOR HF PROGRAM
ICD-9 code Description
398.91 Other rheumatic heart disease, rheumatic HF (congestive)
402.01 Hypertensive heart disease, malignant, with CHF
402.11 Hypertensive heart disease, benign, with CHF
402.91 Hypertensive heart disease, unspecified, with CHF
404.01 Hypertensive heart and renal disease, malignant, with CHF
404.02 Hypertensive heart and renal disease, malignant, with CHF and renal failure
404.11 Hypertensive heart and renal disease, benign, with CHF
404.12 Hypertensive heart and renal disease, benign, with CHF and renal failure
404.91 Hypertensive heart and renal disease, unspecified, with CHF
404.93 Hypertensive heart and renal disease, unspecified, with CHF and renal failure
425.0 Cardiomyopathy
428.0 HF, CHF
428.1 HF, left HF
428.9 HF, unspecified
Health plan members were identified for inclusion in the program based on at least one inpa-
tient claim/encounter or two outpatient claims/encounters within a 12-month period with match-
ing ICD-9 diagnostic codes listed.
diabetes as a comorbid condition. Of health
plan members identified with HF and enrolled
in the program, 641 opted out. There were no
apparent characteristics that distinguished this
group from the participant group on analysis.
Approximately 75% of participants were con-
tinuously enrolled in the program. One hun-
dred twenty deaths (approximately 6%) were
identified among program participants during
the first year (June 1, 2000–May 31, 2001), an
appreciably lower rate than expected in the
general population (i.e., overall death rate from
HF in the United States in 1999 was 18.8%).
Outcome variables for the first year of the
program (June 1, 2000–May 31, 2001 with 6-
month run-out) were compared with partici-
pant historical data in the year prior to en-
gagement in the program (Baseline; January 1,
1999–December 31, 1999 with 6-month run-
out).
CLINICAL PROCESS OUTCOMES
Three clinical processes were examined for
indications of program effectiveness. The data
included patients with systolic as well as dia-
stolic dysfunction.
Appropriate use of ACE inhibitors
For the baseline and report period, the num-
ber and percentage of all program participants
on an ACE inhibitor were calculated. Those
taking an angiotensin receptor blocker or a
combination of hydralazine and nitrates were
included in the numerator.
Appropriate use of beta-blockers
For the baseline and report period, the num-
ber and percentage of program participants on
a beta-blocker following diagnosis of myocar-
dial infarction were calculated.
Appropriate low-density lipoprotein cholesterol
(LDL-C) screening
For the baseline and report periods, the num-
ber and percentage of all program participants
with administrative evidence of having a lipid
profile screening were calculated. LDL-C pro-
files are presumed to be due 12 months fol-
lowing a preceding screening. Table 5 shows
statistically significant (p , 0.001) improve-
ment in appropriate utilization of ACE inhibi-
tors and LDL-C testing for program partici-
pants during the first year of enrollment. While
a 16.4% improvement was observed in beta-
blocker utilization following myocardial in-
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TABLE 4. HF PROGRAM DATA SUMMARY
Baseline Year 1
Total participants 1,637 (100%) 1,973 (100%)
Age groupings
19–34 17 (1.0%) 22 (1.1%)
35–50 118 (7.2%) 102 (5.2%)
51–65 326 (19.9%) 425 (21.5%)
66–80 643 (39.2%) 694 (35.2%)
811 533 (32.6%) 730 (37.0%)
Gender
Female 914 (55.8%) 1,032 (52.3%)
Male 723 (44.2%) 941 (47.7%)
Comorbidities
CHF only 1,070 (65.4%) 1,251 (63.4%)
CHF with diabetes 567 (34.6%) 722 (36.6%)
Continuously enrolled 1,218 (74.4%) 1,456 (73.8%)
TABLE 5. CHANGES IN CLINICAL QUALITY PROCESS MEASURES FOR MEMBERS ENROLLED IN THE HF PROGRAM
Baseline (1,647 members) Year 1 (1,973 members)
Clinical measure N D % N D % x2 (p)
LDL 320 1,637 19.5% 741 1,973 37.6% 139.82 (,0.001)1
ACE2 702 1,389 50.5% 1,092 1,707 64.0% 59.95 (,0.001)1
Post-myocardial infarction 30 70 42.9% 32 54 59.3% 3.28 (n.s.)0.
The percentages with each clinical measure were calculated from the given numerator (N) and denominator (D).
n.s., not significant.
1Critical value at p 5 0.001: 10.827.
2Excludes members with history of renal failure and members with medication allergy to ACE inhibitors who
are not taking an angiotensin receptor blocker or a combination of hydralazine and nitrates.
farction, significance was borderline at the p ,
0.05 level. In all likelihood, the small numbers
account for this.
OTHER OUTCOMES
A comparison of hospital utilization patterns
for the two periods yielded additional positive
findings. Total admissions decreased, and, as
shown in Table 6, reductions were realized in
the number of inpatient admissions per thou-
sand (18.5%), days per thousand (22.2%), and
average LOS (4.4%). Visits to the emergency
room (ER), costly in both human and financial
terms, also decreased in the first year. ER ad-
missions per thousand dropped by 24.6%. A
preliminary examination of readmission rates
showed a decline in the number of readmis-
sions within 30 (18.8%) and 60 (19.2%) days of
discharge with a primary diagnosis of CHF
(ICD-9 code 428.0). Adjusting for the difference
in member months, the percentage reductions
are even greater (231.7% and 232.2%, respec-
tively).
A cost adjustment was necessary in order to
make valid financial comparisons between the
two periods. An “inflation factor,” reflecting
the increase in total medical costs over the pe-
riod, was calculated using medical claims for
the “nondisease” population. The nondisease
population, defined as all health plan members
without any indication of either HF or diabetes,
experienced an 18.2579% increase in medical
costs. This estimate of the overall increase in
costs was used as a multiplier in adjusting base-
line figures for financial comparisons. A com-
parison of inflation-adjusted financial data
from the year prior to implementing the pro-
gram and the first year of the program showed
total medical dollars per member per month
(PM/PM) decreasing by 28%, with the ex-
pected increase in pharmacy costs being offset
by the sharper reduction in medical spending
for urgent and inpatient care (Table 7).
Finally, summary data from a satisfaction
survey of a random sample of 103 (approxi-
mately 6%) program participants yielded find-
ings consistent with the preceding positive out-
comes. Of the respondents, 89.4% rated their
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TABLE 6. CHANGE IN HOSPITAL UTILIZATION WITH HF PROGRAM
Baseline (1,637 members) Year 1 (1,973 members) % change
Admissions per 1,000 1,409.5 1,149.2 218.5%
(total 5 2,008) (total 5 1,949)
Days per 1,000 9,416.2 7,324.9 222.2%
Average LOS 6.7 days 6.4 days 24.4%
ER admissions per 1,000 1,239.6 935.1 224.6%
(total 5 1,766) (total 5 1,586)
TABLE 7. CHANGE IN MEDICAL EXPENDITURES FOR MEMBERS ENROLLED IN THE HF DISEASE MANAGEMENT PROGRAM
Baseline (1/1/99–12/31/99) Year 1 (6/1/00–5/31/01)
(1,637 members) (1,973 members)
Member months 17,096 20,352
Adjusted base1 % change
Medical dollars PM/PM 1,060 1,253.74 870 230.6%
Pharmacy dollars PM/PM 1,066 1,277.71 89 114.5%
Total dollars PM/PM 1,126 1,331.45 959 228.0%
Total medical expenditures $19,248,198 $22,762,514 $19,519,448
1Cost-adjusted for inflation in medical costs: baseline multiplier 18.2579%.
overall satisfaction with the program from
“good” to “excellent.”
DISCUSSION
The observed increases in pharmacy and
ACE inhibitor utilization are indications that
targeted program interventions had the desired
effect on the behavior of both patients and their
physicians. Summary statistics for in-office ed-
ucation with provider offices for the first year
revealed the intensity of program communica-
tion efforts: 317 office/clinic visits, 258 physi-
cian interactions, and 325 clinical staff interac-
tions. One question to be addressed in the
future is why, with the program’s emphasis on
proper use of and dosing with ACE inhibitors,
the utilization of ACE inhibitors in this popu-
lation is less than the utilization reported in
studies of smaller populations.11,12
The phenomenon of “regression to the mean”
is understood to be a factor in explaining de-
creases in medical costs for HF populations, par-
ticularly those identified on the basis of a hos-
pitalization in the baseline year. To minimize the
effect of this potential bias, the program popu-
lation was identified via outpatient as well as in-
patient data, and the analyses include members
with and without hospitalizations for both the
baseline and the report period. Medical ex-
penses for health plan members without evi-
dence of HF or diabetes rose by 18.25% during
the report period, supporting the premise that
the positive financial outcomes observed were
due to the intervention rather than regression to
the mean.
Using cost-adjusted medical expenditures for
the baseline, estimated total cost savings for pro-
gram participants in the first year is $6,359,712.
The average first year savings for a HF program
are 10% beyond the cost of the program. While
the costs of providing this program are not avail-
able for publication, the financial outcomes sug-
gest that the program was cost-effective.
CONCLUSION
HF is aptly described as an “emerging epi-
demic” in the Medicare population. Prospects for
survival for older adults with HF in the United
States are dismal. Growing numbers of adults are
at increased risk for developing HF due to hy-
pertension, diabetes, and/or myocardial infarc-
tion. Evidence of the effectiveness of HF disease
management has been reported in a number of
small population studies. This observational
study extends our understanding of the role of
HF disease management in controlling or re-
tarding the progression of HF, improving par-
ticipants’ health status, and decreasing overall
medical costs in a large population. While it is
recognized that it may take several years to fully
determine its effectiveness, the initial outcomes
of this HF disease management program are uni-
formly positive. Analyses of clinical processes
and a spectrum of other variables, including
medical utilization, financial data, and partici-
pant satisfaction, suggest that the program’s
multiple physician- and patient-focused inter-
ventions are associated with significant im-
provement in outpatient medical management,
reduced inpatient utilization, and decreased
medical costs for participants.
The evidence for HF disease management is
growing, but, if the staggering clinical and eco-
nomic effects of the disease are to be contained,
the health care industry must continue to de-
velop and refine strategies for controlling the
progression of HF in diagnosed patients and
for preventing the onset of HF. Proactive steps
must be taken to control the condition prior to
the onset or early in the course of progressive
left ventricular dysfunction. Predictive models
to identify patients likely to develop HF and
early interventions to head off adverse clinical
events are already being studied. Incorporation
of primary prevention strategies, such as treat-
ment of hypertension and hyperlipidemia and
intensive education for physicians and patients
alike, holds promise for improving or revers-
ing myocardial dysfunction. A multifaceted
program such as the one described could be-
come even more effective by broadening its
scope to include prevention.
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